Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26141052 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL25466578 | 0.83 | — | — | |
| SCHEMBL799181 | 0.83 | CYP3A4 (0.41) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL12263157 | 0.83 | CYP3A4 (0.47) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL824020 | 0.78 | HSD17B10 (0.32) | — | |
| SCHEMBL1106488 | 0.78 | NOS3 (0.36) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL21341339 | 0.77 | HMGCR (0.31) | HMGCR | |
| SCHEMBL22259380 | 0.73 | IDH1 (0.34) | — | |
| SCHEMBL5958520 | 0.70 | KDM4E (0.32) | — | |
| SCHEMBL1162069 | 0.70 | NOS3 (0.35) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023125182-A1 | PROPIONIC ACID DERIVATIVE AND MEDICAL USE THEREOF | 海思科医药集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | Terns, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-11643403-B2 | GLP-1 receptor agonist and use thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-09 | — | — | US | disclosed |
| US-20230013143-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-01-19 | — | — | US | disclosed |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
| US-20220054642-A1 | SUPRAMOLECULAR MODIFICATION OF PROTEINS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-02-24 | — | — | US | disclosed |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | CTI BIOPHARMA CORP. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | CTI BIOPHARMA CORP. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-04-11 | — | — | US | disclosed |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | SIMON FRASER UNIVERSITY (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9447078-B2 | Substituted heterocyclic compounds for disease treatment | ACUCELA INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CHIESI FARMACEUTICI S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013143-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GPR119 | HMGCR 3418/4885CYP3A4 1301/4885CYP2D6 1519/4885 |
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | HMGCR 1637/4885CYP3A4 3202/4885CYP2D6 3926/4885 |
| US-20120088763-A1 | TRIAZOLOPYRIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | CNKSR1, MOK, MAPK1 | HMGCR 3928/4885CYP3A4 1722/4885CYP2D6 657/4885 |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GPR119 | HMGCR 3418/4885CYP3A4 1301/4885CYP2D6 1519/4885 |
| US-11643403-B2 | GLP-1 receptor agonist and use thereof | GLP1R, GIPR, GPR119 | HMGCR 3418/4885CYP3A4 1301/4885CYP2D6 1519/4885 |
| US-20220054642-A1 | SUPRAMOLECULAR MODIFICATION OF PROTEINS | IAPP, PTMS, GLP1R | HMGCR 3484/4885CYP3A4 4384/4885CYP2D6 4596/4885 |
| US-20170216252-A1 | ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES AND METHODS | PDK1, PDK3, PDK2 | HMGCR 1416/4885CYP3A4 3440/4885CYP2D6 3391/4885 |
| US-20130225619-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR DISEASE TREATMENT | CLN6, ALDH1A2, PDE6D | HMGCR 526/4885CYP3A4 4047/4885CYP2D6 3441/4885 |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HMGCR 270/4885CYP3A4 3536/4885CYP2D6 2931/4885 |
| US-11135227-B2 | Oxygen linked pyrimidine derivatives | DPYD, TK2, TK1 | HMGCR 3192/4885CYP3A4 2943/4885CYP2D6 1426/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HMGCR 270/4885CYP3A4 3536/4885CYP2D6 2931/4885 |
| US-20200071339-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | HMGCR 3192/4885CYP3A4 2943/4885CYP2D6 1426/4885 |
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | HMGCR 1665/4885CYP3A4 3624/4885CYP2D6 4352/4885 |
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HMGCR 270/4885CYP3A4 3536/4885CYP2D6 2931/4885 |
| US-20230150998-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | HMGCR 1665/4885CYP3A4 3624/4885CYP2D6 4352/4885 |
| US-20190106427-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | HMGCR 3631/4885CYP3A4 2947/4885CYP2D6 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.